Transplantatsiya stvolovykh kletok kostnogo mozga kak novyy sposob lecheniya pechenochnoy nedostatochnosti. Sovremennoe sostoyanie problemy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The progressive increase in the number of patients with hepatic failure (HF), high morbidity, disability and mortality of these patients indicate a lack of effectiveness of the existing conservative and surgical treatment of this disease and the need for the search of new, more effective treatments. Currently, liver transplantation is the only effective method of treatment, but the ever-increasing deficit of donor organs and the increasing number of patients needing for transplants do not allow wide use of this method of treatment for all patients with HF. The use of stem cells for the treatment of liver diseases represents a new approach to the strategy of treatment of HF. This article focuses on the current state of the problem of treatment of HF using cellular technology through the use of stem/progenitor cells of the bone marrow.

Full Text

Restricted Access

References

  1. Transplant activity in the UK. http:www. report/ current activity reports/ukt/transplant activity uk 2005-2006 v2.pdf (accessed 7 Nov 2007) uktransplant.org.uk/ukt/statistics/transplant activity.
  2. Williams R. Global challenges in liver disease. Hepatol 2006;44:521-26.
  3. Frei P, Geier A, Dutkowski P, M llhaupt B. Liver transplantation. Ther Umsch 2011;68:219-14.
  4. Люндуп А.В., Онищенко Н.А., Крашенинников М.Е., Шагидулин М.Ю. О роли синусоидальных клеток печени и клеток костного мозга в обеспечении регенераторной стратегии здоровой и поврежденной печени (Аналитический обзор) // Вестник трансплантологии и искусственных органов 2010. Т. XII. № 1. С. 78-85.
  5. Люндуп А.В., Онищенко Н.А., Шагидулин М.Ю., Крашенинников М.Е. Стволовые/ прогениторные клетки печени и костного мозга как регуляторы восстановительной регенерации поврежденной печени // Вестник трансплантологии и искусственных органов 2010. Т. XII. № 2. С. 100-07.
  6. Smets F, Najimi MSF, Sokal EM. Cell transplantation in the treatment of liver diseases. Pediatr Transplant 2008;12:6-13.
  7. McKenzie TJ, Lillegard JB, Nyberg SL. Artifi cial and bioartifi cial liver support. Semin Liver Dis 2008;28:210-17.
  8. Онищенко Н.А., ЛюндупА. В., Шагидулин М. Ю., Крашенинников М.Е. Синусоидальные клетки печени и клетки костного мозга как компоненты единой функциональной системы регуляции восстановительного морфогенеза в здоровой и поврежденной печени. // Клет. трансплантол. и ткан. инженерия 2011. Т. VI. № 2. C. 73-87.
  9. Киясов А.П., Гумерова А.А., Титова М.А. Овальные клетки - предполагаемые стволовые клетки печени или гепатобласты? // Клет. трансплантол. и ткан. инженерия 2006. Т. 2. № 4. С. 55-8.
  10. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev 2003;120:117-30.
  11. Sawitza I, Kordes C, Hausinger D. The niche of stellate cells within rat liver. J Hepatol 2009;50(5):1617-24.
  12. Черных Е.Р., Останин А.А., Пальцев А.И. Стволовые клетки в регенерации печени: новые подходы к лечению печеночной недостаточности // Гепатология 2004. Т. 5. С. 24-33.
  13. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002;122:1525-28.
  14. Friedman SL. Reversibility of hepatic fibrosis and cirrhosis-is it all hype? Nat Clin Pract Gastroenterol Hepatol 2007;4:236-37.
  15. Dai LJ, Li HY, et al. The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Res. 2009;2(1):16-25.
  16. Киясов А.П., Одинцова А.Х, Гумерова А.А. и др. Трансплантация аутогенных гемопоэтических стволовых клеток больным хроническими гепатитами // Клет. трансплантол. и ткан. инженерия 2008. T. 3. № 1. C. 70-5.
  17. Russo FP, Alison MR, Bigger BW, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006;130:1807-21.
  18. Люндуп А.В. Применение мезенхимальных стволовых клеток костного мозга при хроническом фиброзирующем повреждении печени (экспериментальное исследование). Дисс. канд. мед. наук. М., 2011. 150 с.
  19. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition. J Biol Chem 2002;277:11069-76.
  20. Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells-basic and clinical implications for novel cell-based therapies. Stem Cells 2007;25:818-27.
  21. Kallis YN, Alison MR, Forbes SJ. Bone marrow stem cells and liver disease. Gut 2007; 56:716-24.
  22. Terai S, Sakaida I. Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients. Hepatol Res 2008;38:72-5.
  23. Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, Wen Y, Rapp JA, Kessler J Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA. J Am Med Assoc 2008;299:925-36.
  24. Banas A, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Osaki M, Kato T, Okochi H, Ochiya T. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J Gastroenterol Hepatol 2009;24:70-7.
  25. Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009;21:1199-205.
  26. Lyra AC, Soares MB, da Silva LF, et al. Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a shortterm improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study. Eur J Gastroenterol Hepatol 2010;22:33-42.
  27. Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 2011;54:820-28.
  28. Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al-Allaf F, M'Hamdi H, Thalji T, Welsh JP, Marley SB, Davies J, Dazzi F, Marelli-Berg F, Tait P, Playford R, Jiao L, Jensen S, Nicholls JP, Ayav A, Nohandani M, Farzaneh F, Gaken J, Dodge R, Alison M, Apperley JF, Lechler R, Habib NA. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colonystimulating factor. Stem Cells 2006;24:1822-30.
  29. Furst G, Schulte am Esch J, Poll LW, Hosch SB, Fritz LB, Klein M, Godehardt E, Krieg A, Wecker B, Stoldt V, Stockschlader M, Eisenberger CF, Modder U, Knoefel WT. Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: Initial experience. Radiology. 2007;243:171-79.
  30. Levicar N, Pai M, Habib NA, Tait P, Jiao LR, Marley SB, Davis J, Dazzi F, Smadja C, Jensen SL, Nicholls JP, Apperley JF, Gordon MY. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif 2008;41:115-25.
  31. Lorenzini S, Isidori A, Catani L, Gramenzi A, Talarico S, Bonifazi F, Giudice V, Conte R, Baccarani M, Bernardi M, Forbes SJ, Lemoli RM, Andreone P. Stem cell mobilization and collection in patients with liver cirrhosis. Aliment Pharmacol Ther 2008;27:932-39.
  32. Houlihan DD, Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology 2008;135:438-50.
  33. Ismail A, Fouad O, Abdelnasser A, Chowdhury A, Selim A. Stem cell therapy improves the outcome of liver resection in cirrhotics J Gastrointest Canc 2010;41:17-23.
  34. Forbes SJ. Stem cell therapy for chronic liver disease-choosing the right tools for the job. Gut 2008;57:153-5.
  35. am Esch IIJS, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: A novel concept to support hepatic regeneration. Stem Cells 2005; 23:463-70.
  36. Gasbarrini A, Rapaccini GL, Rutella S, et al. Rescue therapy by portal infusion of autologous stem cells in a case of drug-induced hepatitis. Dig Liver Dis 2007;39:878-82.
  37. Колосов Н.Г., Величко А.Л., Повещенко О.В., Сиямова Л.Р. Лечение больных циррозом печени путем трансплантации стволовых клеток // Вопр. реконструктивной и пластической хирургии 2004. № 3/4. С. 52-3.
  38. Sakaida I, et al. Cell therapy with bone marrow cell for liver cirrhosis. J Electrophoresis 2006;50:7-12.
  39. Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levicar N, Tait P, Scott M, Marley SB, Jestice K, Glibetic M, Bansi D, Khan SA, Kyriakou D, Rountas C, Thillainayagam A, Nicholls JP, Jensen S, Apperley JF, Gordon MY, Habib NA. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol 2008;103:1952-58.
  40. Kuo TK, Hung S. et al. Stem cell therapy for liver disease: parameters governing the success for using bone marrow mesenchymal stem cells. Gastroenterology 2008;134:2111-21.
  41. Souza BS, Nogueira RC, de Oliveira SA, et al. Current status of stem cell therapy for liver diseases. Cell Transplant 2009;18:1261-79.
  42. Amer ME, El-Sayed SZ, El-Kheir WA, et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Eur J Gastroenterol Hepatol 2011;23:936-41.
  43. Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease. Current Opinion in Gastroenterology 2012;28:203-8.
  44. Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005;23:463-70.
  45. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, Okita K, Sakaida I. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006;24:2292-98.
  46. Lyra AC, Soares MB, da Silva LF, et al. Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. World J Gastroenterol 2007;13:1067-73.
  47. Lyra AC, Soares MB, da Silva LF, et al. A pilot randomized controlled study used to evaluate efficacy of autologous bone marrow mononuclear cells transplantation in patients with advanced chronic liver disease. Hepatology 2007;46(Suppl 1):271A.
  48. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M. et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007;10:459-66.
  49. Mohamadnejad M, Namiri M, Bagheri M, et al. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol 2007;13:3359-63.
  50. Salama H, Zekri ARN, Bahnassy AA, Medhat E, Halim HA, Ahmed OS, Mohamed G, Alim SAA, Sherif GM. Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease. World J Gastroenterol 2010;16:5297-305.
  51. Salama H, Zekri AR, Zern M, Bahnassy A, Loutfy S, Shalaby S, Vigen C, Burke W, Mostafa M, Medhat E, Alfi O, Huttinger E. Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases. Cell Transplant 2010;19:1475-86.
  52. Stutchfield BM, Forbes SJ, Wigmore SJ. Prospects for stem cell transplantation in the treatment of hepatic disease. Liver Transpl 2010;16:827-36.
  53. Lin H, Xu R, Zhang Z, Chen L, Shi M, Wang FS. Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases. Cellular & Molecular Immunology. 2011;8:19-22.
  54. ClinicalTrials.gov. http://clinicaltrials.gov. Accessed April 2010.
  55. Carvalho AB, Quintannilha LF, Dias, et al. Bone marrow multipotent mesenchymal stem cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury. Stem Cells 2008;26:1307-14.
  56. Hoogduijn MJ, Popp FC, Grohnert A, Renner P, van der Laan LJW, Christ B, Shagidulin М., Remuzzi G. and the MISOT Study Group. Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). Transplantation 2010;90(2):124-26.
  57. Franquesa M, Hoogduijn MJ, Eggenhofer E, Pinxteren J, Christ B, Shagidulin M, Obermajer N, Pulin A, Remuzzi G, Dahlke MH, the MiSOT Study Group. Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: Lessons Learned from First Clinical Trials. Transplantation 2013;96(3):234-38.
  58. Peng L, Li H, Gu L. et al. Comparison of biological characteristics of marrow mesenchymal stem cells in hepatitis B patients and normal adults. World J Gastroenterol 2007;13:1743-46.
  59. Fox IJ, Strom SC. To be or not to be: generation of hepatocytes from cells outside the liver. Gastroenterology 2008;134:878-81.
  60. Zhang ZX, Guan LX, Zhang K, et al. A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy 2008;10:134-39.
  61. Zhang Z.X., Guan L.X., Zhang K, et al. Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biol Int 2007;31:645-48.
  62. Cantz T, Manns MP, Ott M. Stem cells in liver regeneration and therapy. Cell Tissue Res 2008;331:271-82.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies